Trials / Not Yet Recruiting
Not Yet RecruitingNCT05371730
A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Nuwacell Biotechnologies Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A clinical study to Evaluate the Safety and Efficacy of NK cells in the treatment of Myelodysplastic Syndromes
Detailed description
This is a single arm, open-label, single-center pilot study. In this study, 15 patients will be enrolled. The primary purpose is to explore the safety including incidence of adverse events and serious adverse events.The secondary purpose is to explore the efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NCR300 | Intravenous infusion of NK cells（NCR300） |
Timeline
- Start date
- 2022-05-30
- Primary completion
- 2025-05-30
- Completion
- 2026-04-30
- First posted
- 2022-05-12
- Last updated
- 2022-05-12
Source: ClinicalTrials.gov record NCT05371730. Inclusion in this directory is not an endorsement.